

Supplementary Table: Comparison of baseline characteristics - study cohort vs. excluded patients

Parameter	Study cohort (N=143)	Excluded patients (N=147)	p-value
Age (years)	58.1 (26-82)	59.1 (25-80)	0.78
Male sex (%)	50	57	0.20
BMI (kg/m ²)	26.4 (17.3-39.1)	25.8 (18-47)	0.81
Genotype (%)			0.14
1a	51 (36)	40 (27)	
1b	64 (45)	66 (45)	
2	7 (5)	6 (4)	
3	17 (12)	33 (23)	
4	2 (1)	2 (1)	
Mixed Genotype	2 (1)		
Treatment regimen (%)			0.017
Sofosbuvir+Ribavirin	31 (22)	25 (17)	
Sofosbuvir+Ledipasvir±Ribavirin	60 (42)	47 (32)	
Sofosbuvir+Daclatasvir±Ribavirin	13 (9)	32 (22)	
Sofosbuvir+Simeprevir±Ribavirin	19 (13)	16 (11)	
Ombitasvir/Paritaprevir/Ritonavir+ Dasabuvir±Ribavirin	20 (14)	24 (16)	
Sofosbuvir+Velpatasvir		3 (2)	
METAVIR N (%) acc. to TE			0.014
F0/F1	34 (24)	15 (10)	
F2	22 (15)	11 (8)	
F3	19 (13)	21 (14)	
F4	68 (48)	78 (53)	
Missing TE		22 (15)	
AST (U/L)	64 (17-258)	70 (22-338)	0.13
ALT (U/L)	73 (19-316)	71 (15-487)	0.27
Bilirubin (μmol/L)	10 (3-100)	13 (3-87)	0.005
Albumin (g/L)	38 (11-46)	36 (20-45)	<0.0001
Platelets (x10 ³ /μL)	165 (42-520)	110 (31-404)	<0.0001
INR	1.06 (0.9-1.3)	1.15 (0.9-2.6)	<0.0001
TE (kPa)	13.1 (3.1-75)	21.5 (4.3-75)	<0.0001
FIB-4 Index	2.9 (0.3-13.2)	5.1 (0.7-24.9)	<0.0001
APRI	1.4 (0.2-6.5)	2 (0.3-13.4)	<0.0001
MELD points	8 (6-16)	9 (7-23)	0.006
CPT N (%)			
A	58 (85)	56 (72)	
B	10 (15)	21 (27)	
C		1 (1)	

Values are given as median and range.

Abbreviation: BMI, body mass index; AST, aspartate aminotransferase; ALT, alanine aminotransferase; INR, international normalized ratio; TE, transient elastography; FIB-4 Index, Fibrosis-4 Index; APRI, AST to platelet ratio index; MELD, model of end stage liver disease; CPT, Child-Pugh-Turcotte score; IU/L, international units per litre; μmol/L, micromole per litre; g/L gram per litre; μL, microliter; kPa, Kilopascal.